---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290588232.md"
description: "Galectin Therapeutics shares are trading higher after the company announced feedback from its recent in-person Type C meeting with the FDA supporting the advancement of belapectin for the treatment of patients with metabolic dysfunction-associated steatohepatitis cirrhosis and portal hypertension."
datetime: "2026-06-23T15:25:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290588232.md)
  - [en](https://longbridge.com/en/news/290588232.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290588232.md)
generator: "portal-rs"
---

# 

Galectin Therapeutics shares are trading higher after the company announced feedback from its recent in-person Type C meeting with the FDA supporting the advancement of belapectin for the treatment of patients with metabolic dysfunction-associated steatohepatitis cirrhosis and portal hypertension.

### Related Stocks

- [GALT.US](https://longbridge.com/en/quote/GALT.US.md)

## Related News & Research

- [Galectin Therapeutics posts corporate presentation highlighting belapectin program for MASH cirrhosis, portal hypertension](https://longbridge.com/en/news/292638312.md)
- [Galectin Therapeutics to file Phase 3 belapectin protocol in Q3 2026 for MASH cirrhosis, portal hypertension](https://longbridge.com/en/news/290558546.md)
- [Inventiva completes last patient visit in NATiV3 Phase 3 trial of lanifibranor in MASH](https://longbridge.com/en/news/297823952.md)
- [Caliway Biopharmaceuticals: CBL-514 delivers significant, safe fat reduction and enhances GLP-1 therapy for weight management](https://longbridge.com/en/news/297535889.md)
- [08:36 ETChoose Health Launches Most Comprehensive At-Home Liver Function Test with 20+ Biomarkers and Clinical Risk Scores](https://longbridge.com/en/news/297326666.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**